ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...

Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...

ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...

ProKidney Corp. (NASDAQ:PROK) saw its stock skyrocket 115% following the release of positive topline results from its Phase 2 ...

US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...

ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with ...

The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...

ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...

ProKidney shares jumped 56% in premarket trading after reporting positive topline results from a select population group in a Phase 2 trial evaluating rilparencel in patients with chronic kidney ...

Over the last 7 days, the United States market has remained flat, though it is up 13% over the past year with an optimistic forecast for earnings growth. In such a landscape, identifying stocks with ...